Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) traded up 2.3% during mid-day trading on Friday . The stock traded as high as $5.01 and last traded at $4.94, with a volume of 819,557 shares traded. The stock had previously closed at $4.83.

PGNX has been the subject of several research analyst reports. Brean Capital restated a “buy” rating on shares of Progenics Pharmaceuticals in a research report on Wednesday, June 15th. Jefferies Group restated a “buy” rating and set a $9.00 price target on shares of Progenics Pharmaceuticals in a research report on Wednesday, April 6th. Zacks Investment Research upgraded Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, July 7th. Finally, Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Progenics Pharmaceuticals in a research report on Monday, April 4th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $10.35.

The stock’s 50-day moving average price is $4.78 and its 200-day moving average price is $4.71. The company’s market capitalization is $356.72 million.

Progenics Pharmaceuticals (NASDAQ:PGNX) last posted its earnings results on Thursday, May 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by $0.05. During the same quarter in the prior year, the firm posted ($0.15) earnings per share. The company earned $2.50 million during the quarter, compared to analysts’ expectations of $3.27 million. The business’s quarterly revenue was up 908.1% compared to the same quarter last year. Equities research analysts anticipate that Progenics Pharmaceuticals Inc. will post $0.12 EPS for the current year.

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.